Characteristics | Number of patients[%] | Number of deaths[%] | Number of OI[%] |
---|---|---|---|
WHO clinical stage | |||
Stage I | 65[19.1] | 6[14.3] | 15[18.1] |
Stage II | 95[27.9] | 9[21.4] | 15[18.1] |
Stage III | 144[42.4] | 17[40.5] | 44[53.0] |
Stage IV | 36[10.6] | 10[23.8] | 9[10.8] |
HAART regimen | |||
Stavudine based | 219[64.4] | 19[45.2] | 60[72.3] |
Zidovudine based | 72[21.2] | 12[28.6] | 18[21.7] |
Tenofovir based | 49[14.4] | 11[26.2] | 5[6.0] |
Base line CD4 | |||
>350 | 5[1.5] | 0[0.0] | 2[2.4] |
200-350 | 94[27.6] | 7[16.7] | 19[22.9] |
100-199 | 139[40.9] | 15[35.7] | 37[44.6] |
<100 | 102[30.0] | 20[47.6] | 25[30.1] |
Risky behaviour | |||
Yes | 120[35.3] | 14[33.3] | 58[69.9] |
No | 220[64.7] | 28[67.7] | 25[30.1] |
Cotrimoxazole Prophylaxis | |||
Yes | 330[97.1] | 42[100.0] | 81[97.6] |
No Fluconazole Prophylaxis |
10[2.9] | 0[0.0] | 2[2.4] |
Yes | 20[5.9] | 8[19.1] | 5[6.0] |
No | 320[94.1] | 34[80.9] | 78[94.0]] |
INH prophylaxis | |||
Yes | 62[18.2] | 7[16.7] | 20[24.1] |
No | 278[81.8] | 35[83.3] | 63[75.9] |